Deutsche Bank
BLCM

Deutsche Bank’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Deutsche Bank’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,268
Closed -$42K – 4980
2019
Q4 		$42K Sell
3,268
-4,911
-60% -$45.3K ﹤0.01% 4041
2019
Q3 		$85K Sell
8,179
-14,647
-64% -$191K ﹤0.01% 3641
2019
Q2 		$386K Sell
22,826
-11,252
-33% -$305K ﹤0.01% 3451
2019
Q1 		$1.15M Buy
34,078
+1,058
+3% +$35.4K ﹤0.01% 2903
2018
Q4 		$963K Buy
33,020
+18,248
+124% +$810K ﹤0.01% 2916
2018
Q3 		$910K Buy
14,772
+822
+6% +$55.6K ﹤0.01% 3399
2018
Q2 		$1.03M Sell
13,950
-3,721
-21% -$290K ﹤0.01% 3404
2018
Q1 		$1.16M Buy
17,671
+6,668
+61% +$504K ﹤0.01% 3216
2017
Q4 		$924K Buy
11,003
+2,425
+28% +$238K ﹤0.01% 3244
2017
Q3 		$990K Sell
8,578
-754
-8% -$79.3K ﹤0.01% 3024
2017
Q2 		$1.09M Buy
9,332
+2,577
+38% +$320K ﹤0.01% 2975
2017
Q1 		$832K Buy
6,755
+235
+4% +$30.8K ﹤0.01% 2774
2016
Q4 		$886K Buy
6,520
+76
+1% +$13.5K ﹤0.01% 2788
2016
Q3 		$1.28M Buy
6,444
+61
+1% +$10.5K ﹤0.01% 2658
2016
Q2 		$825K Buy
6,383
+1,292
+25% +$144K ﹤0.01% 3016
2016
Q1 		$475K Buy
5,091
+388
+8% +$42.2K ﹤0.01% 3250
2015
Q4 		$953K Sell
4,703
-11,904
-72% -$2.13M ﹤0.01% 2900
2015
Q3 		$2.41M Buy
16,607
+8,357
+101% +$1.53M ﹤0.01% 2360
2015
Q2 		$1.75M Buy
8,250
+2,150
+35% +$527K ﹤0.01% 2560
2015
Q1 		$1.41M Sell
6,100
-3,809
-38% -$921K ﹤0.01% 2670
2014
Q4 		$2.28M Buy
+9,909
New +$2.13M ﹤0.01% 2576

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Deutsche Bank's BLCM Position: Q1 2020 in Review

Deutsche Bank sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2020, closing a stake of 3,268 shares — an estimated $42K sold.

Deutsche Bank first reported a position in BLCM in Q4 2014 and held it in 21 quarters. The position peaked at $2.41M in Q3 2015. 29 funds tracked by Wall St. Rank hold BLCM as of Q1 2020.

  • Deutsche Bank reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Deutsche Bank sold 3,268 Bellicum Pharmaceuticals, Inc. shares in Q1 2020, an estimated $42K.
  • Deutsche Bank first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 21 quarters.
  • Deutsche Bank's Bellicum Pharmaceuticals, Inc. position peaked at $2.41M in Q3 2015.
  • 29 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2020.

Based on Deutsche Bank's 13F filing for Q1 2020, filed 14 May 2020.